Other News To Note
• Imprimis Pharmaceuticals Inc., of San Diego, acquired intellectual property for IPI-120, a formulation of tranexamic acid and a derivative of lysine, and an antibiotic. The acquisition was part of an asset purchase agreement with Buderer Drug Company. The combination of tranexamic acid and antibiotic is designed to provide clotting plus protection against infection in transdermal, local, intra-wound applications or intracavity instillation formulations. Terms were not disclosed.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST